Objective: The study objectives were to describe the characteristics and quality of health economics (including pharmacoeconomics) evaluation research studies related to Zimbabwe. Methods: A literature review was conducted to identify health economic evaluation articles. Health economics evaluation, PUBMED, MEDLINE, HealthSTAR, EconLit, and Psychinfo databases and sociological and dissertation abstracts were used to search economic analyses. Only original applied economic evaluations addressing a health-related topic related to Zimbabwe and published in peer reviewed journals in the English language were included. Two reviewers independently evaluated and scored each article in the final sample. Results: The 25 identified articles, published between 1987 and 2005, appeared in 13 different journals (based mostly outside of Zimbabwe). On average, each article was written by three authors, who had mostly medical/clinical training. The number of articles peaked between 1993 and 1997. Based on a 1 to 10 scale, with 10 indicating the highest quality, the mean quality score for all studies was 5.36 (SD = 1.57) and about one-third of the articles were of poor quality (score <4). The quality of articles was statistically significantly related (p <0.10) to the country of journal (non-Zimbabwe = higher), type of publication (non-medical = higher), number of authors (more authors = higher), years of publication (more recent = higher), and primary health intervention (services higher than pharmaceutical interventions). The quality of the articles was not significantly related to the country of current residence of the primary authors, sample size, primary training of the first author, main objective of the study, and type of data (primary vs secondary). Conclusion: The results of the study indicated that the use of health economics (including pharmacoeconomics) evaluation research in Zimbabwe is limited and about one-third of published articles were of poor quality. More and better quality health economics research in Zimbabwe is warranted.